Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Cryptococcal Meningitis

Cryptococcal Meningitis

Cryptococcal meningitis is a life-threatening opportunistic infection predominantly associated with HIV/AIDS, accounting for over 100,000 deaths annually worldwide. However, it also affects individuals with other forms of immunosuppression, including those undergoing immunosuppressive therapy, organ transplant recipients, patients with innate immunodeficiencies, and individuals with hematological disorders. The infection is caused mainly by Cryptococcus neoformans and Cryptococcus gattii,...

Inhibition of Cdk Activity

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

mTOR Signaling and Cancer Progression

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...

Abnormal Proliferation

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Comparative recurrence rates of varicella zoster virus and herpes simplex virus keratitis.

The British journal of ophthalmology·2026

Same author

Corneal Stromal Thinning and Posterior Irregularity After DMEK: Clinical Observations and Biophysical Hypotheses.

Cornea·2026

Same author

Dual crisis: environmental and economic unsustainability in NHS dry eye prescribing.

BMJ open ophthalmology·2026

Same author

Diagnostic Yield of Corneal, Contact Lens, and Lens Fluid Cultures in Microbial Keratitis: A 12-Year Single-Center Study.

Cornea·2025

Same author

Antimicrobial concentrations in the cornea and aqueous humour: a meta-analysis.

The British journal of ophthalmology·2025

Same author

Why take the eye? A systematic review of corneal retrieval methods and donor consent: implications for the UK.

BMJ open ophthalmology·2025

Same journal

Discontinuing Anti-VEGF Therapy in Patients with Neovascular Age-Related Macular Degeneration That Remains Inactive with Treatment at the Maximum Injection Interval.

Clinical ophthalmology (Auckland, N.Z.)·2026

Same journal

Ophthalmic Implications of Ehlers-Danlos Syndrome.

Clinical ophthalmology (Auckland, N.Z.)·2026

Same journal

Diagnostic Value of Pupil Involvement and Yield of Vascular Imaging in Isolated Third Cranial Nerve Palsy: A 10-Year Retrospective Study.

Clinical ophthalmology (Auckland, N.Z.)·2026

Same journal

Short-Term Preliminary Results of Outcomes with and without Tenonectomy During Open Conjunctival XEN45 Gel Stent Implantation.

Clinical ophthalmology (Auckland, N.Z.)·2026

Same journal

Chemical and Thermal Ocular Burns in Children: A Retrospective Single-Center Study of Etiology, Clinical Characteristics, and Outcomes.

Clinical ophthalmology (Auckland, N.Z.)·2026

Same journal

Two-Year Follow-Up of the MINI WELL Non-Diffractive Extended Depth-of-Focus Intraocular Lens: A Retrospective Observational Study.

Clinical ophthalmology (Auckland, N.Z.)·2026

See all related articles

Search research articles

Related Experiment Video

Updated: Jun 21, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Cyclosporin-A associated malignancy.

Jonathan M Durnian¹, Rosalind M K Stewart, Richard Tatham

¹St. Pauls Eye Unit, Royal Liverpool University Hospital, Liverpool, United Kingdom.

Clinical Ophthalmology (Auckland, N.Z.)

|August 12, 2009

Summary

This summary is machine-generated.

This review examines the cancer risk associated with cyclosporin, an immunosuppressant used in ophthalmology for intraocular inflammation. It provides clinicians with data to assess patient risks and establish monitoring protocols.

Keywords:

ciclosporine cyclosporin cyclosporine malignancy neoplasm and cancer development

Related Experiment Videos

Last Updated: Jun 21, 2026

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Area of Science:

Ophthalmology
Immunosuppression
Oncology

Background:

Cyclosporin is widely used in ophthalmology to treat sight-threatening intraocular inflammation.
General immunosuppression is a known risk factor for malignancy.
Previous studies indicate a potential cancer risk associated with cyclosporin use.

Purpose of the Study:

To analyze and review studies on malignancy development linked to cyclosporin.
To extrapolate findings to the ophthalmic setting.
To aid clinicians in assessing individual patient risks and implementing monitoring strategies.

Main Methods:

Comprehensive literature review of relevant studies.
Analysis of data concerning cyclosporin-associated malignancy.
Extrapolation of findings to ophthalmic clinical practice.

Main Results:

The review synthesizes existing evidence on the link between cyclosporin and cancer.
Specific risks within the ophthalmic context are extrapolated.
Guidance for clinical risk assessment and monitoring is proposed.

Conclusions:

Cyclosporin use in ophthalmology requires careful consideration of malignancy risk.
Clinicians should be aware of the potential for cancer development in patients on cyclosporin.
A structured monitoring approach is recommended for patients undergoing cyclosporin treatment.